Financial Performance - The company's revenue for Q1 2025 was ¥169,429,129.41, representing a 29.61% increase compared to ¥130,725,745.26 in the same period last year[8]. - Net profit attributable to shareholders reached ¥11,973,873.82, a significant increase of 226.47% from ¥3,667,660.56 in the previous year[8]. - The net profit excluding non-recurring gains and losses was ¥9,683,298.46, marking a 1,448.20% increase from ¥625,453.36 year-on-year[8]. - The basic and diluted earnings per share were both ¥0.09, reflecting a 200.00% increase compared to ¥0.03 in the same period last year[8]. - Operating profit for the current period was ¥11,119,439.09, significantly higher than ¥1,764,717.02 from the previous period, marking a substantial increase[21]. - Net profit for the current period reached ¥11,973,873.82, compared to ¥3,667,660.56 in the previous period, representing a growth of 226.5%[22]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥1,331,270,025.58, a 1.13% increase from ¥1,316,426,388.19 at the end of the previous year[8]. - Total liabilities amounted to ¥285,025,808.71, slightly up from ¥283,728,930.39 in the previous period[19]. - The company's cash and cash equivalents at the end of the reporting period amount to ¥80,859,628.03, a decrease from ¥84,519,980.92 at the beginning of the period[17]. - Total assets at the end of the reporting period are ¥1,331,270,025.58, compared to ¥1,316,426,388.19 at the beginning[18]. - The total non-current assets decreased to ¥746,779,546.00 from ¥762,108,412.74[18]. Cash Flow - The net cash flow from operating activities was negative at -¥1,876,307.90, a decline of 120.23% compared to ¥9,275,848.83 in the same period last year[8]. - Cash flow from operating activities was ¥118,756,546.12, an increase from ¥109,738,736.88 in the previous period[24]. - Net cash flow from operating activities was -$1.88 million, a decrease from $9.28 million in the previous period, indicating a decline in operational efficiency[25]. - Cash inflow from operating activities totaled $128.08 million, slightly lower than $133.02 million in the previous period, showing stable operational cash generation[25]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 15,315[14]. - The largest shareholder, Hongbo Zhiyuan (Hong Kong) Medical Technology Co., Ltd., holds 27.71% of shares, totaling 38,675,000 shares[14]. - The top ten shareholders include several investment firms, with the largest being Hongbo Zhiyuan, followed by An Rongchang and Jiang Shengli, indicating a concentration of ownership[14]. Operating Costs and Expenses - Total operating costs amounted to ¥157,965,262.18, up from ¥135,325,810.41, reflecting a growth of 16.8%[20]. - Research and development expenses decreased to ¥8,726,167.99 from ¥11,274,826.18, a reduction of 22.6%[21]. - Cash outflow for employee compensation was $67.05 million, an increase from $62.02 million, reflecting rising labor costs[25]. Government Support and Other Income - The company received government subsidies amounting to ¥615,660.33 during the reporting period, which are closely related to its normal business operations[9]. - The company reported a decrease in other comprehensive income, with a net amount of -¥81,158.69 for the current period[22]. - The company received $1.55 million in tax refunds, compared to $0.52 million previously, indicating improved tax recovery[25]. Borrowings and Receivables - Short-term borrowings increased by 76.45% to ¥17,664,171.34, up from ¥10,011,000.00[12]. - Accounts receivable increased to ¥124,302,105.64 from ¥98,645,259.36, reflecting a growth of approximately 26%[18]. - The company reported a significant increase in accounts receivable, which rose by 739.78% to ¥9,312,016.35 from ¥1,108,865.20[12].
泓博医药(301230) - 2025 Q1 - 季度财报